Biocompatibles

This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages) This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Biocompatibles" – news · newspapers · books · scholar · JSTOR (November 2009) (Learn how and when to remove this message) This article needs to be updated. The reason given is: The company was acquired in 2010. Additional details may require update.. Please help update this to reflect recent events or newly available information. (October 2019) (Learn how and when to remove this message)

Biocompatibles plc

Company type	Public company
Traded as	LSE: BII
Industry	Pharmaceutical industry
Founded	1984
Headquarters	Farnham, UK
Key people	Gerry Brown (Chairman of the board)
Products	Drug Eluting Beads
Revenue	£9.1 million (2007)[1]
Operating income	£6.9 million (2007)[1]
Net income	£6.2 million (2007)[1]
Number of employees	89 (2007)[1]
Website	www.biocompatibles.com

Biocompatibles International plc was a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010,^[2] which was, in turn, acquired by Boston Scientific in 2019.^[3][4]

Approved oncology products were supplied and marketed from facilities in Farnham, Surrey, UK and Oxford, Connecticut.

Products included drug-eluting bead products that are used in more than 35 countries for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and other cancers. The company supplied and marketed brachytherapy products (radiation-delivering seeds) that are used to treat prostate cancer.^[5]

Its UK research and development facilities were engaged in licensing and in new product development based on the company's core drug delivery technologies in the treatment of cancers.

Its Cellmed unit in Alzenau, Germany, was developing a drug-eluting bead product for the treatment of stroke based on proprietary stem cell technology. Cellmed was also developing a GLP-1 analogue for the treatment of diabetes and obesity partnered with AstraZeneca.

Biocompatibles had collaborative agreements with Bayer HealthCare Pharmaceuticals Inc., Medtronic Inc. and Merz Pharma.

In the 1970s Dennis Chapman (1927–1999) at London's Royal Free Hospital. Chapman and his colleagues were responsible for groundbreaking research in the area of biocompatibility – the ability of a material to interface within the body without provoking an adverse biological response. They identified phosphoryl-choline (PC), a substance present in the human cell membrane, as one of the primary natural materials responsible for biocompatibility.

In 1984 Chapman founded Biocompatibles, which patented PC technology to develop it for commercial healthcare applications. In 2002, the company expanded to a new field based upon embolisation therapy, a minimally invasive treatment for tumors or vascular malformations based upon compressible PVA embolic microspheres.

Biocompatibles has been publicly traded on the London Stock Exchange since 1995^{[6][failed verification][non-primary source needed]} (LSE:BII).

In 2010, the company was acquired by BTG plc for about 156 million pounds.^[7]

In 2019, its new parent company BTG was acquired by Boston Scientific for around US$4.2 billion.^[3]

Biocompatibles has a patent portfolio defending three biomedical polymer systems.

• The NFil Technology licensed from the Biocure affiliate of Novartis' Ciba Vision subsidiary, which is used in the Drug-Eluting Beads programme;
• The CellMed alginate technology, CellBeads, which is required for the encapsulation of biological agents; and the PC technology that was the group's original platform;
• A variety of more product-specific drug delivery inventions for the delivery of both chemical and biological agents.

Research and products are centered on the controlled and accurate delivery of drugs to patients with certain forms of cancer or vascular problems. Research is focused on the use of drug-eluting beads, which can be accurately delivered to the point of need. Once metabolized, these beads release the prescribed drug at a pre-determined rate.